These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 11328421)
1. A clinical study of urine basic fetoprotein and urine polyamine as tumor markers in epithelial cancer of the urinary tract. Sato D; Kase T; Tajima M; Sawamura Y; Matsushima M Int J Urol; 2001 May; 8(5):217-21. PubMed ID: 11328421 [TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation of basic fetoprotein in bladder cancer]. Ichikawa T; Nakayama Y; Yamada D; Saegusa M; Asano S; Aramaki K Nihon Hinyokika Gakkai Zasshi; 2000; 91(7-8):579-83. PubMed ID: 10965742 [TBL] [Abstract][Full Text] [Related]
3. [The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies]. Tsujii T; Yonese J; Kojima S; Tari K; Ishii M; Seino Y Nihon Hinyokika Gakkai Zasshi; 1990 Jun; 81(6):829-34. PubMed ID: 1698231 [TBL] [Abstract][Full Text] [Related]
4. [Urinary tumor marker for urothelial cancer]. Ohtani M; Iwasaki A; Shiraiwa H Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491 [TBL] [Abstract][Full Text] [Related]
5. Urinary beta-glucuronidase activity as an initial screening test for urinary tract malignancy in high risk patients. Comparison with conventional urine cytologic evaluation. Ho KJ; Kuo SH Cancer; 1995 Aug; 76(3):473-8. PubMed ID: 8625129 [TBL] [Abstract][Full Text] [Related]
6. [Clinical evaluation of urinary basic fetoprotein and the BTA test for detection of bladder cancer]. Imamura M; Inoue K; Megumi Y; Nishimura M; Ohmori K; Nishimura K Hinyokika Kiyo; 2000 Oct; 46(10):705-9. PubMed ID: 11215195 [TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Miyanaga N; Akaza H; Ishikawa S; Ohtani M; Noguchi R; Kawai K; Koiso K; Kobayashi M; Koyama A; Takahashi T Eur Urol; 1997; 31(2):163-8. PubMed ID: 9076459 [TBL] [Abstract][Full Text] [Related]
8. Urinary basic fetoprotein in the diagnosis and follow-up of patients with urothelial carcinoma. Kigure T; Wakayama Y; Satoh Y; Fujieda N; Yoshida K; Harada T Cancer; 1996 Apr; 77(8):1529-34. PubMed ID: 8608539 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test. Del Nero A; Esposito N; Currò A; Biasoni D; Montanari E; Mangiarotti B; Trinchieri A; Zanetti G; Serrago MP; Pisani E Eur Urol; 1999 Feb; 35(2):93-7. PubMed ID: 9933801 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer. Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642 [TBL] [Abstract][Full Text] [Related]
12. [Urinary NMP22 as a new marker in patients with transitional cell carcinoma]. Muzzonigro G; Minardi D; Galosi AB; Recchioni A; De Sio G; Polito M Arch Ital Urol Androl; 1999 Jun; 71(3):171-7. PubMed ID: 10431409 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of a urine-based tumor marker for screening lower urinary tract in low-risk patients with asymptomatic microscopic hematuria. Sagnak L; Ersoy H; Gucuk O; Ozok U; Topaloglu H Urol Int; 2011; 87(1):35-41. PubMed ID: 21654152 [TBL] [Abstract][Full Text] [Related]
14. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder. Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432 [TBL] [Abstract][Full Text] [Related]
15. Indications for ureteropyeloscopy based on radiographic findings and urine cytology in detection of upper urinary tract carcinoma. Takao A; Saika T; Uehara S; Monden K; Abarzua F; Nasu Y; Kumon H; Jpn J Clin Oncol; 2010 Nov; 40(11):1087-91. PubMed ID: 20581003 [TBL] [Abstract][Full Text] [Related]
16. Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report. Lodde M; Mian C; Wiener H; Haitel A; Pycha A; Marberger M Urology; 2001 Sep; 58(3):362-6. PubMed ID: 11549481 [TBL] [Abstract][Full Text] [Related]
17. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Hakenberg OW; Fuessel S; Richter K; Froehner M; Oehlschlaeger S; Rathert P; Meye A; Wirth MP Urology; 2004 Dec; 64(6):1121-6. PubMed ID: 15596183 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of DNA image cytometry and urinary cytology with cells from voided urine in the detection of bladder cancer. Planz B; Synek C; Robben J; Böcking A; Marberger M Urology; 2000 Nov; 56(5):782-6. PubMed ID: 11068301 [TBL] [Abstract][Full Text] [Related]
19. [Urinary cytology in cases of bladder cancer: a critical evaluation]. Rathert P Urologe A; 2003 Jul; 42(7):908-11. PubMed ID: 12898033 [TBL] [Abstract][Full Text] [Related]
20. Current practice of urinary cytology. A four-year-practice review with 3,995 cytological specimens examined. Thienpont L; Mestdagh J; Morelle V; Fonteyne E; De Galan JL; Lornoy W; Becaus I Acta Urol Belg; 1983; 51(1):18-30. PubMed ID: 6858794 [No Abstract] [Full Text] [Related] [Next] [New Search]